Latest news with #NasdaqCopenhagen
Yahoo
21-07-2025
- Business
- Yahoo
Danske Bank share buy-back programme: transactions in week 29
Company announcement no. 34 2025Danske BankBernstorffsgade 40DK-1577 København VTel. + 45 33 44 00 0021 July 2025Page 1 of 1Danske Bank share buy-back programme: transactions in week 29On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the "Market Abuse Regulation") and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the "Safe Harbour Rules"). The following transactions on Nasdaq Copenhagen A/S were made under the share buy-back programme in week 29: Number of shares VWAP DKK Gross value DKK Accumulated, last announcement 8,482,830 234.6883 1,990,821,369 14 July 2025 103,147 258.1543 26,627,842 15 July 2025 97,316 256.5786 24,969,203 16 July 2025 95,525 256.6734 24,518,727 17 July 2025 139,946 254.1745 35,570,705 18 July 2025 200,000 254.3732 50,874,640 Total accumulated over week 29 635,934 255.6258 162,561,116 Total accumulated during the share buyback programme 9,118,764 236.1485 2,153,382,484With the transactions stated above, the total accumulated number of own shares under the share buy-back programme corresponds to 1.092% of Danske Bank A/S' share BankContact: Claus Ingar Jensen, Head of Group Investor Relations, tel. +45 25 42 43 70 Attachment Danske Bank Company announcement UK Weekly SBB announcement Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
Semi Annual Report 2025
Lysaker, 10 July 2025 The semi annual report for securities funds managed by Storebrand Asset Management AS was approved by the Board of Directors today, and has now been released (only in Norwegian language). The report includes the below 10 funds which are listed on Nasdaq Copenhagen, and can be downloaded here, or at Regards Storebrand Asset Management AS Contacts: Henrik Budde Gantzel, Director, Frode Aasen, Product Manager, fdc@ Fund name and share class Symbol ISIN SKAGEN Focus A SKIFOA NO0010735129 SKAGEN Global A SKIGLO NO0008004009 SKAGEN Kon-Tiki A SKIKON NO0010140502 SKAGEN m2 A SKIM2 NO0010657356 SKAGEN Vekst A SKIVEK NO0008000445 Storebrand Indeks – Alle Markeder A5 STIIAM NO0010841588 Storebrand Indeks – Nye Markeder A5 STIINM NO0010841570 Storebrand Global ESG Plus A5 STIGEP NO0010841604 Storebrand Global Solutions A5 STIGS NO0010841612 Storebrand Global Multifactor A5 STIGM NO0010841596 Storebrand is Norway's largest private asset manager with an AuM of around DKK 900 billion, and a leading Nordic provider of sustainable pensions and savings. The company has been a global pioneer in ESG investing for over 30 years, offering broad and scalable solutions for both institutional and private investors in the Nordic region and other European countries. In Denmark, Storebrand delivers sustainable investment solutions and client value through a multi-boutique platform, with the brands Storebrand Funds, SKAGEN Funds, Cubera Private Equity, Capital Investment and a majority ownership of AIP. Attachment Halvårsrapport 2025
Yahoo
24-06-2025
- Business
- Yahoo
FLSmidth announces share buy-back programme of up to DKK 1.4 billion
COMPANY ANNOUNCEMENT NO. 11-2025 FLSmidth & Co. A/S 20 June 2025 Copenhagen, Denmark FLSmidth & Co. A/S ('FLSmidth') today announces a share buy-back programme of up to DKK 1.4 billion to be completed before the next Annual General Meeting, which is expected to be held on 24 March 2026. This marks the company's first share buy-back programme since company's decision to initiate a share buy-back programme is supported by a significantly stronger and more stable financial performance (ref. Company Announcement no. 8-2025). Through strategic portfolio optimisation, our order backlog has over the past years undergone a material de-risking, with a shift toward more resilient, higher-margin technology and service offerings and reduced exposure to volatile or non-strategic projects. The decision is furthermore supported by the recently announced divestments of the Cement business (ref. Company Announcement no. 10-2025) and corporate headquarters in Valby, Copenhagen (ref. Company Announcement no. 9-2025). While pursuing value-accretive investments remains an important strategic focus point for FLSmidth, the Board of Directors continues to prudently balance additional investments in growth with returning value to shareholders. Given the substantial headroom to the company's targeted leverage ratio (ref. Company Announcement no. 8-2025), the Board of Directors sees an opportunity to return capital to the company's shareholders while still maintaining the ambition to pursue attractive growth opportunities. The share buy-back programme is carried out with the objective of adjusting the capital structure of FLSmidth and to meet obligations arising from share-based incentive programmes. Accordingly, any shares repurchased under the share buy-back programme that are not intended to cover obligations related to the company's share-based incentive programmes are ultimately intended to be proposed for cancellation at a General Meeting following the completion of the share buy-back share buy-back programme is initiated pursuant to the authorisation granted to the Board of Directors at the Annual General Meeting on 2 April 2025, allowing the company in the period until the next Annual General Meeting to be held in 2026 to acquire its own shares up to an aggregate nominal amount corresponding to 10 percent of the company's share capital. The consideration must according to the authorisation not deviate by more than 10% from the official price quoted on Nasdaq Copenhagen at the time of acquisition. Prior to the commencement of the share buy-back programme, FLSmidth held a total of 567,002 shares, corresponding to 0.98 percent of the company's share capital, as treasury shares. The share buy-back programme will be executed in accordance with Article 5 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Regulation'). FLSmidth has appointed BNP Paribas to manage the programme. The manager will make all trading decisions independently of and without involving of the share buy-back programmeThe share buy-back programme commences on Wednesday 25 June 2025 and will end no later than Friday 20 March 2026. Under the share buy-back programme, FLSmidth may repurchase shares up to a maximum amount of DKK 1.4 billion, and no more than 4,600,000 shares, corresponding to approximately 8 percent of the share capital of the company. The shares bought back on each trading day may not exceed 25 percent of the average daily trading volume over the 20 trading days preceding the date of purchase. Shares acquired under the share buy-back programme may not be bought at a price exceeding the higher of (i) the share price of the last independent transaction, and (ii) the highest independent bid on the shares on the trading venue where the transaction is executed. Further, shares may not be bought at a price deviating by more than 10% from the official price quoted on Nasdaq Copenhagen at the time of acquisition. FLSmidth will be entitled to suspend the share buy-back programme at any time. Should the share buy-back programme be suspended, FLSmidth will announce this in a Company Announcement and the manager will stop buying back shares in the market. In accordance with the Safe Harbour Regulation, FLSmidth will as a minimum for every 7th trading day issue an announcement in respect of transactions made under the share buy-back programme. Contacts: Investor RelationsAndreas Holkjær, +45 24 85 03 84, andh@ Denholt, +45 21 69 66 57, jli@ MediaJannick Denholt, +45 21 69 66 57, jli@ FLSmidth FLSmidth is a full flowsheet technology and service supplier to the global mining industry. We enable our customers to improve performance, lower operating costs and reduce environmental impact. MissionZero is our sustainability ambition towards zero emissions in mining by 2030. We work within fully validated Science-Based Targets, have a clear commitment to improving the sustainability performance of the global mining industry and aim to become carbon neutral in our own operations by 2030. Attachment FLSmidth Company Announcement no. 11-2025
Yahoo
12-06-2025
- Health
- Yahoo
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,' said Martin Lange, executive vice president for Development at Novo Nordisk. 'We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.' Novo Nordisk is now planning to initiate a phase 3 development programme with amycretin for adults with overweight or obesity during the first quarter of 2026. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral Amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 Amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Company announcement No 17 / 2025 Attachment CA250612-amycretin-to-phase-3-clean
Yahoo
12-06-2025
- Health
- Yahoo
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to phase 3,' said Martin Lange, executive vice president for Development at Novo Nordisk. 'We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the phase 3 programme.' Novo Nordisk is now planning to initiate a phase 3 development programme with amycretin for adults with overweight or obesity during the first quarter of 2026. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral Amycretin Phase 1 trial - The trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 Amycretin Phase 1b/2a trial - The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Company announcement No 17 / 2025 Attachment CA250612-amycretin-to-phase-3-cleanSign in to access your portfolio
